BioLineRx : Annual Report by Foreign Issuer (Form 20-F)
A >5-fold increase. The addition of motixafortide to G-CSF also allowed 88.3% of patients to undergo transplantation after only one apheresis session, compared to 10.8% in the G-CSF arm - an... | March 16, 2022
United States United Kingdom Kode Biotech Biokine Therapeutics Ltd Drug Administration Agalimmune Development Agreement
Source: marketscreener.com